Nichola Cooper1, Quentin A Hill2, John Grainger3, John-Paul Westwood4, Charlotte Bradbury5, Drew Provan6, Jecko Thachil7, Nicholas Ramscar8, Anuja Roy9. 1. Department of Haematology, Hammersmith Hospital, London, United Kingdom. 2. Department of Haematology, The Leeds Teaching Hospital, Leeds, United Kingdom. 3. Department of Pediatric Haematology, Royal Manchester Children's Hospital, Manchester, United Kingdom. 4. Department of Haematology, University College London Hospital, London, United Kingdom. 5. Bristol Haematology and Oncology Centre, University of Bristol, Bristol, United Kingdom. 6. Department of Haematology, Barts and the London School of Medicine, London, United Kingdom. 7. Department of Haematology, Central Manchester University Hospital, Manchester, United Kingdom. 8. Novartis UK, London, United Kingdom. 9. Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Abstract
BACKGROUND: Recent evidence suggests that in patients with immune thrombocytopenia (ITP) with a stable response on thrombopoietin receptor agonists, treatment may be tapered and/or discontinued. OBJECTIVES: The objective of this study was to provide a guide for tapering and discontinuation of TPO-RA therapy in patients with ITP, based on hematologist survey results, existing evidence, and expert consensus. PATIENTS/ METHODS: UK hematologists completed a survey to characterize self-reported practice patterns related to TPO-RA tapering and discontinuation in patients with ITP. Using a modified Delphi panel approach, ITP experts developed consensus statements regarding the use of TPO-RA tapering and discontinuation. RESULTS: Survey respondents estimated that 30-34% of their patients were suitable for tapering or discontinuation and that 29-35% of these patients required treatment re-initiation after an average treatment-free interval of 86-106 days. No clear predictors of patient suitability or response to tapering or discontinuation were identified. The ITP expert consensus was that approximately 30% of patients are eligible for tapering and discontinuation, which may be considered after 6-12 months for patients demonstrating an adequate treatment response (platelet count >50,000/µL at ≥75% of assessments in the preceding 6 months). Treatment re-initiation may be considered if the platelet count decreases or if the patient becomes symptomatic. Individual differences need to be taken into account when considering TPO-RA tapering or discontinuation. CONCLUSIONS: Tapering and discontinuation of TPO-RA therapy may be considered for certain patients with ITP. Further study is needed to better predict patients likely to achieve sustained off-treatment responses after tapering and discontinuation. The Author(s). Published by S. Karger AG, Basel.
BACKGROUND: Recent evidence suggests that in patients with immune thrombocytopenia (ITP) with a stable response on thrombopoietin receptor agonists, treatment may be tapered and/or discontinued. OBJECTIVES: The objective of this study was to provide a guide for tapering and discontinuation of TPO-RA therapy in patients with ITP, based on hematologist survey results, existing evidence, and expert consensus. PATIENTS/ METHODS: UK hematologists completed a survey to characterize self-reported practice patterns related to TPO-RA tapering and discontinuation in patients with ITP. Using a modified Delphi panel approach, ITP experts developed consensus statements regarding the use of TPO-RA tapering and discontinuation. RESULTS: Survey respondents estimated that 30-34% of their patients were suitable for tapering or discontinuation and that 29-35% of these patients required treatment re-initiation after an average treatment-free interval of 86-106 days. No clear predictors of patient suitability or response to tapering or discontinuation were identified. The ITP expert consensus was that approximately 30% of patients are eligible for tapering and discontinuation, which may be considered after 6-12 months for patients demonstrating an adequate treatment response (platelet count >50,000/µL at ≥75% of assessments in the preceding 6 months). Treatment re-initiation may be considered if the platelet count decreases or if the patient becomes symptomatic. Individual differences need to be taken into account when considering TPO-RA tapering or discontinuation. CONCLUSIONS: Tapering and discontinuation of TPO-RA therapy may be considered for certain patients with ITP. Further study is needed to better predict patients likely to achieve sustained off-treatment responses after tapering and discontinuation. The Author(s). Published by S. Karger AG, Basel.
Authors: James B Bussel; David J Kuter; James N George; Robert McMillan; Louis M Aledort; George T Conklin; Alan E Lichtin; Roger M Lyons; Jorge Nieva; Jeffrey S Wasser; Israel Wiznitzer; Reggie Kelly; Chien-Feng Chen; Janet L Nichol Journal: N Engl J Med Date: 2006-10-19 Impact factor: 91.245
Authors: Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George Journal: Blood Date: 2008-11-12 Impact factor: 22.113
Authors: James B Bussel; David J Kuter; Vinod Pullarkat; Roger M Lyons; Matthew Guo; Janet L Nichol Journal: Blood Date: 2008-11-03 Impact factor: 22.113
Authors: Hasan Rizvi; Tom Butler; Mariarita Calaminici; Indraraj U Doobaree; Raghava C Nandigam; Dimitri Bennett; Drew Provan; Adrian C Newland Journal: Br J Haematol Date: 2015-03-05 Impact factor: 6.998
Authors: Drew Provan; Roberto Stasi; Adrian C Newland; Victor S Blanchette; Paula Bolton-Maggs; James B Bussel; Beng H Chong; Douglas B Cines; Terry B Gernsheimer; Bertrand Godeau; John Grainger; Ian Greer; Beverley J Hunt; Paul A Imbach; Gordon Lyons; Robert McMillan; Francesco Rodeghiero; Miguel A Sanz; Michael Tarantino; Shirley Watson; Joan Young; David J Kuter Journal: Blood Date: 2009-10-21 Impact factor: 22.113
Authors: Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely Journal: Blood Adv Date: 2019-12-10